Continuing or Stopping Low Dose Glucocorticoids in GPA Dr. Mike Putman reports about plenary session abstract 0774 (the TAPIR study) about how and when patients can stop steroids in GPA. #ACR24 https://t.co/OWqN0jmkc1 https://t.co/foOaVRtGiV

• https://buff.ly/4fQhcT1

RheumNow’s expanded coverage of the #ACR24 meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its Faculty.

RheumNow Day 3 Recap: ACR Convergence 2024 Highlights https://t.co/jFIATPKlp7

• Dr. John Cush

I've shared some thoughts on @RheumNow on methotrexate, tocilizumab, and baricitinib in PMR based on #ACR24 https://t.co/WXiW1nLN4k

• JAKs and Other Drugs in PMR | RheumNow

TNFis preventing cancer compared to placebo, and JAKi being neutral to placebo and maybe preventing haem cancers also. #ACR24 abstract 0989 was certainly provocative. I've shared my thoughts on @RheumNow https://t.co/yQFoUGifEN

• Do TNFis and JAKis Prevent Cancer!? | RheumNow

Pathophysiological pathways in neuropsychiatric SLE. 2 components: -Ischaemic -Inflammatory Zahi Touma @RheumNow #ACR24 https://t.co/wwlSSSpOIU

• https://x.com/synovialjoints/status/1858635468436615207/photo/1

Great project by @kekuchinad to evaluate how PFTs bias our assessment and contribute to disparities @CaoilfhionnMD @jhrheumatology @BayviewMedicine @RheumNow #ACR24 https://t.co/b5pAn3e9AR https://t.co/opzWrZ1NH5

• Race Neutral PFTs in Scleroderma Improves Equity
• https://twitter.com/ericdeinmd/status/1858211728707686717

Potential Impact of Weight Loss Drugs in Rheumatic Diseases Dr. Arthur Kavanaugh highlights a session regarding weight loss and improvement in disease outcomes, specific weight loss drugs (SGL-2 and GLP-1), along with downsides when patients stop these medications. Reporting… https://t.co/Ilu2FXK2xi https://t.co/7CKSnfuey4

Yang et al. Cranial vessel wall MRI in GCA. Quantitated with PEG score. PEG score ocular GCA>non-ocular GCA>non-GCA. Decreases with treatment. @RheumNow #ACR24 Abstr#2650 https://t.co/e26urOpb7V https://t.co/eekQbzmKYm

• Extent of Vascular Inflammation on Cranial Vessel Wall MRI and Ophthalmic Compl…
• https://x.com/RichardPAConway/status/1858616166966497497/photo/1

A#2651 Vasculitis w VEXAS 81 men, median age 67 - 27% had evid of vasculitis, variable size vessel 22% SVV- 17/18 cutaneous, one peritubular capillaritis on renal bx 2.5% MVV (2 cutan), LVV (2 carotid thickening, 1 had +TA bx), ANCA+ @RheumNow #ACR24 https://t.co/puablIBLCP

• https://x.com/ericdeinmd/status/1858616964383375444/photo/1

What factors are assoc with uptake of newer meds in RA? ➡️Incr use of b/tsDMARDs over 10yrs ➡️Use of newer drugs lower in older ppl, socioeconomic deprived & Asian/Black ppl Could this indicate disparities in access to meds? How can we best address this? Ab2608 #ACR24 @RheumNow

Subsets of lupus arthritis. Kenneth Kalunian @RheumNow #ACR24 https://t.co/ZmHui126zr

• https://x.com/synovialjoints/status/1858619265659670978/photo/1

Sullivan et al. Vasculitis in VEXAS. 81 patients. 27% vasculitis. Cutaneous SVV 20%, AAV 2.5%, cutaneous MVV 2.5%, LVV 2.5%. @RheumNow #ACR24 Abstr#2651 https://t.co/AV3RcuSKpV https://t.co/xrax025TzP

• Vasculitis Associated with VEXAS Syndrome - ACR Meeting Abstracts
• https://x.com/RichardPAConway/status/1858619438720757790/photo/1